HOXA10 is necessary for embryonic patterning of skeletal elements, but its function in bone formation beyond this early developmental stage is unknown. Here we show that HOXA10 contributes to osteogenic lineage determination through activation of Runx2 and directly regulates osteoblastic phenotypic genes. In response to bone morphogenic protein BMP2, Hoxa10 is rapidly induced and functions to activate the Runx2 transcription factor essential for bone formation. A functional element with the Hox core motif was characterized for the bone-related Runx2 P1 promoter. HOXA10 also activates other osteogenic genes, including the alkaline phosphatase, osteocalcin, and bone sialoprotein genes, and temporally associates with these target gene promoters during stages of osteoblast differentiation prior to the recruitment of RUNX2. Exogenous expression and small interfering RNA knockdown studies establish that HOXA10 mediates chromatin hyperacetylation and trimethyl histone K4 (H3K4) methylation of these genes, correlating to active transcription. HOXA10 therefore contributes to early expression of osteogenic genes through chromatin remodeling. Importantly, HOXA10 can induce osteoblast genes in Runx2 null cells, providing evidence for a direct role in mediating osteoblast differentiation independent of RUNX2. We propose that HOXA10 activates RUNX2 in mesenchymal cells, contributing to the onset of osteogenesis, and that HOXA10 subsequently supports bone formation by direct regulation of osteoblast phenotypic genes.
Patterning and development of the skeleton are complex processes involving signaling proteins and transcription factors that function as determinants for bone formation. Among the principal regulatory cascades for the development of the skeleton are Hox genes that determine the position and shape of a tissue element (19, 54) and the bone morphogenetic proteins (BMPs), which induce the differentiation of mesenchymal cells to osteoblast and chondroblast lineages (18, 84) . BMP2 signaling leads to the induction of a number of transcription factors, including RUNX2 (28) and OSTERIX (42, 56) , which are essential for bone development (34, 45, 69) . Several HOX and homeodomain proteins have been identified as molecular targets of BMP-mediated gene transcription during early stages of bone formation by microarray gene expression profiling studies (3, 33) . The present study was aimed at characterizing a BMP2-inducible gene, the Homeobox a10 (HOXA10) gene, as a candidate for contributing to commitment and development of the osteoblast phenotype.
Mammalian Hox genes (homologues of the Drosophila homeotic genes) encode transcription factors crucial in regional development along the anterior-posterior axis during embryogenesis (44, 64) . The mouse and human genomes contain 39 Hox genes, which are grouped into four clusters, Hoxa, Hoxb, Hoxc, and Hoxd, positioned on four separate chromosomes in 13 paralogs (38, 44) . Hoxa10 is a member of the Abdominal B (Abd B) class of homeobox protein-encoding genes, representing the most 5Ј genes in the cluster consisting of paralog genes from Hoxa 9 to Hoxa 13 (4, 44, 50) . The corresponding class of homeobox proteins binds preferentially to a consensus core of TTAT or TTAC, which is distinct from the TAAT homeodomain consensus core binding site recognized by MSX and DLX proteins (4) . HOXA10 DNA binding is influenced by flanking sequences and the formation of complexes with HOXA10interacting proteins of the MEIS and PBX classes of transcription factors, as well as other coregulatory proteins, such as histone deacetylase 2 (13, 51, 60, 72, 74, 81) .
Several of the Hox genes are essential for normal skeletal development (31, 64) . The nonparalogous Hoxa10 and Hoxd11 genes cooperate in the development of the forelimbs and axial skeleton and are required to globally pattern the mammalian skeleton (6, 7, 26, 68, 80) . Inactivation of the paralogous Hoxa10 and Hoxd10 genes results in alterations in the formation of the forelimbs and hind limbs. Hoxa10 Ϫ/Ϫ mice revealed an active role for the gene in modeling the femur, tibia, and fibula (12, 79) . Transgenic expression of HOXA10 in presomitic mesoderm of the mouse resulted in vertebrae without ribs (11) . HOXA10 is expressed in the presomitic mesoderm, which develops into the axial skeleton and cooperates with other Hox genes (e.g., Hoxd11) for normal skeletal development (11, 26, 31, 64) . Despite the considerable genetic evidence that HOXA10 has critical skeletal functions, target genes of HOXA10 in bone have not been identified.
In this study we have characterized HOXA10 regulation of the key osteogenic factor Runx2, as well as RUNX2 target genes, identifying Hoxa10-specific regulatory elements in pro-moters of the Runx2, osteocalcin (OC), alkaline phosphatase, and bone sialoprotein osteoblast-related genes. This discovery of a Hox regulatory factor in activating Runx2 provides novel insights for a mechanism that regulates a transcription factor essential for bone formation (43, 58) . Although Runx2 is rapidly induced in response to BMP2 and present in developing limbs, somites, and mesenchymal condensations prior to chondrogenic and osteoblast differentiation (23, 46, 76) , a Smadresponsive element has not been defined. Thus, BMP2-induced HOXA10 represents a key regulator of Runx2 transcription during embryogenesis. Our studies also show that HOXA10 can regulate osteoblast genes independent of RUNX2. We have thus identified an additional role for HOXA10 in postnatal bone formation and maintenance of the osteoblast phenotype. We propose that HOXA10 functions in two capacities: as a component of a BMP2 signaling cascade prior to RUNX2 to mediate the developmental induction of osteogenesis and during osteoblast differentiation to regulate the temporal expression of bone phenotypic genes to drive osteoblast maturation through mechanisms involving chromatin remodeling of gene promoters.
(Brian Weiner's contribution to this paper is in fulfillment of a Worcester Polytechnic Institute undergraduate thesis project.) P1 promoter site 1 (WT, 5ЈG CAT TCA  GAA GGT TAT AGC TTT 3Ј; mutant, 5ЈG CAT TCA GAA GGC GAT AGC  TTT 3Ј [underlining indicates the HOXA10 binding site, and boldface indicates the mutation]) were end labeled with [␥-32 P]ATP by use of T4 polynucleotide kinase (New England Biolabs, Massachusetts). The detailed procedures have been described previously (34) . Anti-HOXA10 (N20) or a nonspecific antibody (either ␣-actin or normal immunoglobulin G [IgG] as indicated) (Santa Cruz) were used for the immunoshift studies. Complexes were visualized by autoradiography of a 6.5% acrylamide gel.
Immunoblotting. Each well of a six-well plate was lysed in 50 l lysis buffer (2% sodium dodecyl sulfate [SDS], 10 mM dithiothreitol, 10% glycerol, 12% urea, 10 mM Tris-HCl [pH 7.5], 1 mM phenylmethylsulfonyl fluoride, 1ϫ protease inhibitor cocktail [Roche], 25 M MG132 [proteosome inhibitor from Calbiochem]) and boiled for 5 min. Equal amounts of total protein were analyzed by SDS-polyacrylamide gel electrophoresis and probed with suitable antibodies. Immunocomplexes were detected using Western Lightning chemiluminescence reagent (Perkin Elmer, Boston, MA).
Antibodies. The following antibodies were purchased from Santa Cruz Biotechnology. HOXA10 N20 (SC-17158) was for chromatin immunoprecipitation (ChIP) and EMSA, and A20 (5C-17159) was for Western blotting. RUNX2 antibodies were PEBP2␣A (M-70 [SC-10758]), PEBP2␣A (C-19 [SC-8566]), and actin (I-19 [SC-1616] ). Mouse monoclonal RUNX2 antibody was a generous gift from Yoshi Ito and Kosei Ito (National University, Singapore, Republic of Singapore). Anti-hyperacetylated histone H4 (Penta) and anti-trimethyl histone H3 (Lys4), clone MC315, were purchased from Upstate Cell Signaling Solutions (Charlottesville, VA). The mouse monoclonal anti-Xpress antibody was obtained from Invitrogen (Carlsbad, CA). Mouse monoclonal antibody against RNA polymerase II (Pol II) (clone 8WG16) was obtained from Covance (Princeton, NJ) and used in ChIP studies.
ChIP assays. The procedure for ChIP in primary rat osteoblasts has already been described (34) . Control primer pairs from 3Ј untranslated regions (UTR) of the genes were used to verify specific and nonspecific binding of DNA fragments (Table 1) . IgG antibody was used as a control for nonspecific pull-down of immunocomplexes. Sequential ChIP studies were performed using the primary pull-down from one antibody, which was divided into equal aliquots for the second pull-down with antibodies specific for coregulatory molecules. Instead of being eluted in 1% SDS and 100 mM Na 2 HCO 3 after cross-linking and washing, immunocomplexes were eluted in 10 mM dithiothreitol. The eluate was further diluted 1:40 in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM Tris-HCl [pH 8.1], 167 mM NaCl) and used for the second immunoprecipitations. Aliquots (2 to 3 l) of DNA samples from different pull-downs were assayed by either radioactive labeling or RT-QPCR using Power SYBR green PCR master mix (Applied Biosystems, California) for the detection of specific DNA fragments with primers in the proximal promoters of bonerelated genes that encompass the Hoxa10 binding sites ( Table 1) .
Immunohistochemistry and immunofluorescence. Long bones from normal newborn mice were fixed with 4% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.4, for 48 h, dehydrated, and embedded in paraffin by standard procedures. Paraffin-embedded tissues (5-m sections) were immunoperoxidase labeled and blocked by 0.3% H 2 O 2 in absolute methanol for 30 min at room temperature. To reveal antigens, sections were put in a 1 mM Tris solution, pH 9.0, supplemented with 0.5 mM EGTA. The sections for RUNX2 immunohistochemistry were heated in a microwave oven for 10 min after EGTA treatment, while a normal steaming antigen retrieval method was used for HOXA10. Nonspecific immunoglobulin binding was prevented by incubating the sections in 50 mM NH 4 Cl for 30 min followed by blocking with phosphate-buffered saline supplemented with 1% bovine serum albumin, 0.05% saponin, and 0.2% gelatin. Serial sections were incubated overnight at 4°C with anti-rabbit RUNX2 (M-70 and C-19) or antigoat HOXA10 (N20) antibody diluted (1:100) in phosphate-buffered saline supplemented with 0.1% bovine serum albumin and 0.3% Triton X-100. Equal amounts of the respective blocking peptides (2 g/ml) for HOXA10 and RUNX2 were also used. Normal IgG was used as a nonspecific control. Immunolabeling controls were performed by using antibodies preabsorbed with immunizing peptides. Labeling was visualized with the horseradish peroxidase-conjugated secondary antibody (P448, 1:200; Dako).
MC3T3 cells were plated at a density of 0.6 ϫ 10 5 cells/well on gelatin-coated coverslips in six-well plates. Cells were processed for in situ immunofluorescence analyses, which were carried out as described previously (39) . HOXA10 was detected by a goat polyclonal antibody at a dilution of 1:100 (Santa Cruz Biotechnology). The secondary antibody used was Alexa 488-anti-goat antibody (Molecular Probes) at a dilution of 1:800. For overexpressed HOXA10 protein, HeLa cells at 0.5 ϫ 10 5 cells/well on gelatin-coated coverslips were transfected with 0.5 g of Hoxa10 expression construct, and 24 h after transfection the coverslip was processed for immunofluorescence study (39) . Xpress-HOXA10 was detected by a mouse monoclonal antibody against the Xpress tag at a dilution of 1:3,000 (Invitrogen). The secondary antibody used was Alexa 568anti-mouse antibody (Molecular Probes, Eugene, OR) at a dilution of 1:800. Slides were examined on a Zeiss Axioplan 2 microscope fitted with epifluorescence (Carl Zeiss, Jena, Germany) attached to a charge-coupled-device camera. Images were saved and processed using Metamorph imaging software, version 6.1 (Universal Imaging, Downingtown, PA).
RNA interference (RNAi) of Hoxa10. The mouse MC3T3-E1 osteoblastic cells at 30 to 50% confluence were transfected using Oligofectamine (Invitrogen Life Technologies) with small interfering RNA (siRNA) duplexes specific for murine uate the target specificity and knockdown efficiency. The cells were also transfected with control siRNA duplexes specific for green fluorescent protein by use of the same concentrations to check the transfection efficiency. The siRNA experiment was carried out for 72 h. Total RNA and proteins from the specific siRNA oligonucleotide-treated, untreated, Oligofectamine-treated and nonspecific-oligonucleotide-treated cells were analyzed by Western blotting and RT-QPCR. To study chromatin modifications after Hoxa10 siRNA treatment, cells were harvested 72 h posttransfection and used for immunoprecipitation with trimethyl histone H3K4 and hyperacetylated H4 antibody for ChIP analyses.
RESULTS
Hoxa10 is a BMP2-responsive gene correlating to the induction of Runx2-mediated osteogenesis. Hoxa10 was identified as an early BMP2-responsive gene in an Affymetrix cDNA profiling study of BMP2-mediated osteogenic induction of premyogenic C2C12 cells (3) . During the 24-h time course, Hoxa10 expression clustered into a group of genes in which the osteogenic transcription factor Runx2 was also present. We carried out independent experiments in this study and quantitated gene expression by RT-QPCR to validate the microarray report ( Fig. 1A) . Both Hoxa10 and Runx2 mRNAs are present at very low levels in untreated cells, immediately upregulated by BMP2 within 2 h, and then partly downregulated, but they exhibit a second spike at 6 h. After the 8-h commitment point to osteogenesis, when bone phenotypic markers (alkaline phosphatase and OC) are expressed (3), Hoxa10 mRNA remains at a steady state, while Runx2 continuously increases.
To further evaluate the expression of Hoxa10 and Runx2 during the development of the osteoblast phenotype, we examined the temporal expression of Hoxa10 during the differentiation of osteoprogenitor MC3T3 cells. Hoxa10 is endogenously expressed at low levels in the proliferating cells (day 7) and is induced four-to fivefold upon the maturation of the phenotype, concurrent with cellular multilayering (day 10 in this experiment) ( Fig. 1B ). Peak mRNA expression levels of Hoxa10 are transient and downregulated by 50% by day 16, the onset of mineral deposition in MC3T3 cells. Expression of Runx2 and alkaline phosphatase phenotypic genes continuously increases during differentiation. These observations suggest that Hoxa10 expression is important at the early stages of osteoblast differentiation. We further showed that either treatment of pluripotent C3H10T1/2 cells with BMP2 or growth of adherent bone marrow cells in osteogenic media results in a twofold increase in Hoxa10 concomitant with the expression of the osteoblast phenotype (data not shown). These studies implicate HOXA10 in establishing early events in the development of the osteoblast phenotype.
To appreciate the role of HOXA10 in osteogenesis in vivo, we examined its expression in bone cell populations in situ in relation to endochondral bone formation and skeletal development. Sections of long bones and vertebrae from newborn mice were treated with specific antibodies to detect RUNX2 and HOXA10 (Fig. 2 ). We found strong expression of HOXA10 in the periosteum, the hypertrophic chondrocyte zone of the growth plate, and osteoblasts on all bone surfaces. RUNX2 was also expressed in these cell populations. Weak expressions of HOXA10 and RUNX2 were found in the flattened cells that represent the prehypertrophic chondrocyte phenotype. It is noteworthy that both HOXA10 and RUNX2 were absent from the epiphyseal chondrocytes that represent permanent hyaline cartilage. Similar observations were made for vertebrae tissue. We conclude from these studies that RUNX2 and HOXA10 are expressed in osteogenic lineage cells and maturing chondrocytes at the growth plate in both the axial and appendicular skeletons. While most immunohistochemical staining is nuclear, some hypertrophic chondrocytes and osteoblasts have cytoplasmic staining representing either background or specific HOXA10 staining. To address a potential artifact of cytoplasmic staining, we examined the endogenous localization of HOXA10 by in situ immunofluorescence in isolated osteoblasts. Punctate nuclear staining was observed, with a few foci detected in the cytoplasms of MC3T3 cells (Fig. 2B ). However, 100% nuclear localization was observed with exogenously expressed HOXA10 protein in HeLa cells by use of the Xpress tag antibody (Fig. 2C) . These findings indicate that the localization of the HOXA10 isoform with transactivation activity is nuclear.
The coordinate BMP2 induction of Hoxa10 and Runx2 in response to BMP2-induced osteogenesis in several cell models, taken together with the profiles of expression of these genes during the maturation of MC3T3 cells as well as their coexpression in osteogenic lineage cells, suggests a functional relationship between RUNX2 and HOXA10.
The P1 bone-related promoter of Runx2 and the endogenous Runx2 gene are regulated by HOXA10. As activating signals on the Runx2 promoter during early stages of embryonic development are limited, we pursued the characterization of a Hoxa10 regulatory element in the bone-related Runx2 P1 promoter. Examination of the Runx2 0.6-kb promoter, which has been studied for its regulation in osseous and nonosseous cells, revealed the presence of three putative Hox consensus sequences. Two TTAT-containing core sequences (4, 24) and one sequence with a TTAC core (72) , which binds HOXA9 well but HOXA10 with a low frequency (4, 73) , are present in the proximal promoter ( Fig. 3A) . These sequences differ from the TAAT binding site for homeodomain proteins of the MSX and DLX classes (34, 45) . To identify the HOXA10-responsive regulatory element(s) in the Runx2 gene, deletion mutation analyses were performed with both NIH 3T3 (nonosseous) and MC3T3 (osseous) cells cotransfected with Runx2 promoter deletion fragments and HOXA10. The endogenous protein levels of HOXA10 are slightly higher in the MC3T3 preosteoblasts than in the NIH 3T3 fibroblasts (Fig. 3B , control lanes) which may be contributing to the basal expression of the promoter constructs in MC3T3 cells, where the Ϫ351 fragment is reduced 20% (Fig. 3C ). In the presence of exogenous HOXA10, a 2-to 2.5-fold increase in promoter activity of the Ϫ600, Ϫ490, and Ϫ458 fragments is observed, suggesting that the proximal TTAT site 1 is sufficient for HOXA10 regulation of Runx2 (Fig. 3C ). Furthermore, complete loss of HOXA10 responsiveness occurs with the Ϫ351 Runx2-Luc fragment, which lacks the putative site 1 for HOXA10 binding. Furthermore, mutation of site 1 blocked HOXA10-mediated transcriptional activation (Fig. 3D ). The site 2 mutation had no effect on HOXA10 induction of Runx2, i.e., the construct retained the same 2.5-fold activation level as the WT. The TTAC core site, located at Ϫ420/Ϫ417, cannot be functional, as the site 1 mutation showed no HOXA10-induced change in promoter activity. Taken together, these results are consistent with the location of a functional Hoxa10 site in the proximal promoter fragment at Ϫ353/Ϫ351, a regulatory element mediating HOXA10 activation of the Runx2 P1 promoter. Sequence-specific binding of HOXA10 to the proximal regulatory motif was validated in EMSA by WT and mutant oligonucleotide binding studies ( Fig. 4A and B) . Confirming the mutation studies, site 2 does not form a HOX protein-DNA complex with osteoblast nuclear extracts ( Fig. 4B ). In contrast, site 1 binds in vitro-transcribed and -translated (IVTT) HOXA10 protein and HOXA10 from nuclear extracts of osteoblasts, as indicated by antibody supershifts (Fig. 4B ). To rule out the possibility of redundant HOX protein binding to site 1 because other HOX factors are expressed in osteoblasts (20, 30) , we further examined the interaction of other paralogous HOX proteins expressed in MC3T3 cells with Runx2 site 1. Antibody specificities were established by testing IVTT HOXA10 protein bound to probe with supershift analyses using antibodies specific to other Abd B class proteins. None of these antibodies cross-reacted with HOXA10 ( Fig. 4C , left panel), nor did they supershift/block shift the HOXA10 complex from nuclear extracts bound to Runx2 site 1 (Fig. 4C, right  panel) . In conclusion, the deletion and site-directed mutagenesis of putative Hox elements in the 0.6-kb Runx2 promoter demonstrates that HOXA10 protein binds preferentially to the Runx2 TTAT site 1.
To address the biological significance of the HOXA10-mediated positive regulation of the Runx2 gene at the onset of osteoblast differentiation, cellular levels of HOXA10 were inhibited by siRNA knockdown in two osteogenic cell models. Preosteoblastic MC3T3 cells were treated with several Hoxa10 siRNA duplex oligonucleotides for 72 h, which resulted in the inhibition of HOXA10 cellular protein levels compared with the nonsilencing duplex control. Figure 5A shows results for two siRNAs, one of which only modestly decreased HOXA10 protein (siRNA2; decrease of 10 to 15% from densitometry measurements), while siRNA1 exhibited a robust dose-dependent inhibitory effect on HOXA10 and also caused a significant dose-related decrease in RUNX2 protein (Fig. 5B) .
The potency of HOXA10 in regulating Runx2 at the onset of BMP2-induced osteogenesis was examined with C2C12 cells (Fig. 5C ). Cells were first treated with siRNA for 48 h, which was followed by BMP2 for 2 h. Hoxa10 siRNA resulted in a 50% knockdown of Hoxa10, a decrease which prevented the twofold BMP2 induction of Hoxa10 mRNA in the control (absence of Hoxa10 siRNA). Runx2 was reduced nearly 75% by Hoxa10 siRNA in the absence of BMP2. In the presence of BMP2 and Hoxa10 siRNA, Runx2 was not induced to a level over that seen for the control. However, the inhibition was less (33% decrease) than in the absence of BMP2 (Ͼ50% decrease). This finding is likely the consequence of BMP2 induction of other transcription factors that can upregulate Runx2. Thus, we were prompted to examine levels of Dlx3, a BMP2 early response gene in this cell model (35) . Dlx3 was induced over the control in the presence of Hoxa10 siRNA and BMP2 (data not shown). These studies define HOXA10 as a signifi- Functional recruitment of HOXA10 to promoters of Runx2 and other osteoblast-related genes. To gain further insight into the in vivo regulation of Runx2 transcription by HOXA10 during the development of the osteoblast phenotype, we performed ChIP assays with primary rat calvarial osteoblasts, which undergo a well-documented sequence of maturation stages (59) . Western blot analysis for RUNX2 and HOXA10 protein levels during the differentiation time course shows that a low basal level of HOXA10 protein is present in proliferative osteoblasts (day 4), while RUNX2 protein is not observed until day 6 ( Fig. 6A) . When bone-like nodules form on day 10, HOXA10 is upregulated twofold, increases again on day 12, and remains at a constitutive level into the mineralization stage (day 20). RUNX2 protein levels increase continuously during osteoblast maturation but are reduced on day 20 (heavily mineralized cultures). These findings emphasize that HOXA10 is present in osteoprogenitors prior to RUNX2 protein appearance and that HOXA10 may function throughout differentiation.
The timing of recruitment of HOXA10 to the Runx2 gene in relation to transcription was determined by ChIP assays at the indicated days during differentiation (Fig. 6B ). Trace levels of HOXA10 above those for the IgG control were observed on days 4 and 5 in different experiments. Consistently, we found that RNA Pol II and HOXA10 were robustly associated with the promoter, beginning on day 6, when RUNX2 protein was first detected in this experiment (Fig. 6B ). This coordinate occupancy was reproducible over multiple time courses (data not shown). HOXA10 remained bound to the Runx2 promoter but dissociated on day 20, the late mineralization stage, a finding consistent with decreased RUNX2 protein levels in the cells (Fig. 6A ) and decreased RNA Pol II association with the promoter (Fig. 6B ). On the other hand, RUNX2 association with its own promoter gradually increased from day 6 to day 20 in late mineralization, reflecting its role in maintaining physiologic transcription by autoregulation (21) . Thus, HOXA10 contributes both to the significant activation of Runx2 expression throughout the early stages of osteoblastogenesis and to the regulation of physiologic levels in mature osteoblasts by dissociation from the Runx2 promoter. ChIP studies allow for assays of transcription factors associated with different promoters in the same sample. We therefore examined the promoters of several osteoblast genes for potential Hoxa10 binding sites and designed primers to amplify the DNA of the appropriate promoter domain. Table 2 shows the putative sequences. We examined the direct regulation of the osteoblast-specific OC gene, which is highly regulated by RUNX2 (40) . A Hox binding site was located in the proximal Ϫ208 promoter segment, which exhibits tissue-restricted expression (37) (Fig. 7A ). Using a Ϫ208 OC-CAT reporter construct, we found a two-to threefold increase in promoter activity in response to HOXA10 in multiple experiments (Fig.  7B ). By ChIP analysis (Fig. 7C ), we found that HOXA10 is associated with OC chromatin 24 h prior to RUNX2 association. During osteoblast differentiation, both HOXA10 and RUNX2 binding were enhanced on days 8 and 9, when OC mRNA first began to accumulate (Fig. 7D) , consistent with increased Pol II binding on day 9 (Fig. 7C ). After this initial induction of OC, HOXA10 association with the OC promoter diminished in the matrix maturation and mineralization stages, while RUNX2 remained present on OC chromatin. The coordinate increase in HOXA10 and RUNX2 binding to OC prompted us to examine the combined effects of HOXA10 and RUNX2 on OC promoter activity. We found an additive effect on promoter activity as a result of the coexpression of the factors (Fig. 7B ), suggesting that the Hoxa10 and Runx2 regulatory elements function independently on the OC promoter, not synergistically. Taken together, these results demonstrate HOXA10 supports the regulation of OC expression earlier than RUNX2 and significantly contributes to OC-induced mRNA.
We also examined the promoters for alkaline phosphatase (ALP) and bone sialoprotein (BSP) and found Hoxa10-regulatory elements ( Table 2 and Fig. 8 ). In proliferating primary osteoblasts, ALP (Fig. 8A) and BSP (Fig. 8B ) are expressed, but at low levels. Association of HOXA10 with the ALP and BSP promoters was confirmed by ChIP assay with the osteoprogenitor cells (day 4) as well as with postproliferative mature osteoblasts (days 12 and 20). Interestingly, HOXA10 association with the promoter of ALP, the early marker of osteoblasts, was most prominent on day 4 and reduced on day 20, when ALP mRNA is downregulated. In contrast, both HOXA10 binding to the BSP promoter and BSP expression (mRNA) increased during differentiation. These observations suggest that HOXA10 directly regulates genes independent of RUNX2 binding.
These ChIP studies reveal that the recruitment of RUNX2 to most gene promoters continuously increases during differentiation, with similar profiles in each case (Fig. 8C) . Figure 8C summarizes the profiles (from densitometry measurements of the ChIPs) of RUNX2 and HOXA10 association with four gene promoters. In contrast to RUNX2, HOXA10 has distinct profiles of association/dissociation with individual gene promoters during differentiation. It is notable that HOXA10 association to the gene promoters is critical to gene regulation independent of HOXA10 cellular levels (Fig. 8C, left panel) . These differences may reflect very dynamic functional characteristics of HOXA10 promoter binding in relation to the regulation of the transcription of osteoblast genes at stages of osteoblast phenotype development. We conclude from these studies that Hoxa10 functional elements are present in multiple osteoblast genes, including the OC, bone sialoprotein, and alkaline phosphatase genes, contributing to their regulated expression.
HOXA10 regulates osteoblast genes both dependent on (in MC3T3 cells) and independent of (in Runx2 null cells) RUNX2. The ChIP studies (Fig. 6, 7 , and 8) suggest that HOXA10 may regulate osteoblast genes that are significant functional components of bone, either synergistically, by increasing Runx2 expression, or directly, through Hox regulatory motifs. We therefore examined the consequences of the depletion of Hoxa10 on the endogenous expression of these skeletal markers of osteoblast differentiation by RT-QPCR (Fig. 9A) . MC3T3 cells were treated with Hoxa10 siRNA for 48 h, which reduced Runx2 gene expression threefold. Dose-dependent decreases of the early osteoblast markers ALP and BSP were also observed, as was a twofold reduction in OC mRNA. Exoge- nous expression of HOXA10 in MC3T3 cells (Fig. 9B) shows that Runx2 and ALP expression is increased twofold, while the mature osteoblast-related genes OC and BSP are induced between five-and eightfold.
To address the possibility of the direct regulation of osteoblast genes, we tested the competency of HOXA10 to induce their expression independent of RUNX2 by using a TERT-immortalized preosteoblastic cell line derived from Runx2 null mice (1) (Fig. 9C ). Cells were transfected with Hoxa10 and/or Runx2 expression vector, and total cellular RNA was analyzed 24 h later. Expression profiling by real-time PCR revealed that HOXA10 induced OC, ALP, and BSP to an extent the same as that seen for their induction by RUNX2 (three-to fourfold for OC or BSP and five-to sixfold for ALP). The presence of HOXA10 and RUNX2 together resulted in an additive induction for OC and BSP, genes whose expression continues to increase during differentiation ( Fig. 7 and 8 ), but not ALP (Fig. 8 ).
HOXA10 activation of osteogenic genes OC, ALP, and BSP in Runx2 null cells, taken together with the association of HOXA10 with binding elements in these promoters, supports a RUNX2-independent direct role for HOXA10 in promoting osteoblast differentiation. However, these promoters are also Runx2 responsive, and HOXA10 directly induces Runx2, thereby contributing to HOXA10 RUNX2-dependent transcription of osteoblast genes. The BMP2-initiated induction of Hoxa10, Runx2, and other transcriptional factors (e.g., DLX3 and DLX5) indicates that these factors all contribute specific regulatory functions to support bone formation. This combinatorial control is schematically illustrated in Fig. 9D .
HOXA10 contributes to chromatin modification of osteoblast target genes for induced transcription. The early recruitment of HOXA10, prior to RUNX2, on the OC, ALP, and BSP gene promoters suggests that HOXA10 may contribute to remodeling the chromatin of these phenotypic genes. The re-modeling of chromatin structure is mediated in part by enzymes that topologically alter DNA interactions with histones or that covalently modify the core histone proteins H3 and H4 (41) . Acetylation of histone H4 and H3K4 methylation are modifications that strongly correlate with transcriptionally active chromatin (10, 75, 77) . To test this hypothesis, we examined the effects of Hoxa10 depletion on histone acetylation and H3K4 methylation of gene promoters, which reflect transcriptionally active chromatin. Cells were treated with Hoxa10-specific siRNA for 72 h (Fig. 10A ), and these chromatin modifications were assayed by ChIP analysis for the four bone phenotypic genes (Fig. 10B ). We confirmed a 50% knockdown of Hoxa10 by siRNA and a 50% reduction in HOXA10 binding to OC, ALP, and BSP promoters but a modest decrease in the recruitment of HOXA10 to the RUNX2 promoter ( Fig. 10B , left panels). We observed a significant 50% reduction in the acetylation of OC, BSP, and Runx2 chromatin but a modest decrease in ALP chromatin acetylation in cells treated with Hoxa10 siRNA relative to control levels (nonsilencing siRNA) ( Fig. 10B ). On the other hand, we found in multiple studies (n ϭ 3) a significant decrease in the H3K4 methylation of ALP and BSP, while the methylation of OC and Runx2 chromatin was less decreased.
Upon RNAi-mediated depletion of HOXA10, we found an impairment of histone modifications in the chromatin of the Runx2, OC, ALP, and BSP genes, suggesting that coregulatory proteins with histone acetyltransferase (HAT) activity may be present in a HOXA10 complex associated with chromatin. To address this mechanism of chromatin remodeling by HOXA10 binding to target genes, we examined the association of coregulatory proteins having HAT activity, p300 and CBP, with HOXA10 ( Fig. 10C ). We performed sequential chromatin immunoprecipitation studies (ChIP-reChIP) to determine the in vivo interactions of HOXA10 with coactivator proteins on the Hoxa10
Osteoblast gene sequences were obtained from the NCBI database. HOXA10-allowed nucleotides (Ϫ4 to Ϫ1 and 5 to 7) outside the core (1, T; 2, T; 3, A; 4, T or C) are as follows for the indicated positions, as detailed in the work of Benson et al. (4): Ϫ1, TϾG; Ϫ2, TϾG; Ϫ3, AϾTϾG; Ϫ4, AϾG ϭ T; 5, TϾGϾA; 6, AϾGϾC; 7, CϾA ϭ G. HOXA9 can bind to TTAC as well as to TTAT sites, as shown by Shen et al. (72) (73) (74) .
b Runx2 functional Hoxa10 sequence (site 1) ( Fig. 3 and 4 ). c HOXA10 binds IVTT protein but not in nuclear extracts and is nonresponsive to Runx2 site 2 ( Fig. 3 and 4 ). d Uncharacterized Runx2 binding site with TTAC motif (Ϫ419/Ϫ416). e The corresponding HOXA10 binding site indicated in nucleotides across species and obtained for different bone marker genes (Runx2, OC, BSP, and ALP).
Runx2 and OC promoters in ROS 17/2.8 cells. These cells robustly express endogenous bone-related factors. A first ChIP was performed with HOXA10 antibody, followed by pull-down with antibodies specific to each coregulatory protein (Fig.  10C ). Although the interaction of HOXA10 is greater with the OC gene than with the Runx2 promoter, p300 and CBP are found in the HOXA10 complex associated with both genes. These results demonstrate that the presence of HOXA10 on bone target genes can contribute to epigenetic alterations in chromatin that favor transcription (summarized in Fig. 10D ).
DISCUSSION
In this study we have defined a principal role for HOXA10 in contributing to osteoblast cell fate and differentiation. Hoxa10, which is essential for skeletal patterning, is characterized in our studies as an activator of Runx2 and three phenotypic genes (ALP, BSP, and OC) that represent progressive stages of osteoblastogenesis. Our data support the concept that HOXA10 functions in initiating osteogenic gene expression but that the bone phenotype is not fully established until Runx2 is expressed. The evidence includes the following: (i) the finding that Hoxa10 and Runx2 are immediate-response genes to the BMP2 morphogenetic signal and exhibit similar expression profiles during the induction of the osteoblast phenotype in C2C12 cells; (ii) the exhibition by both genes of robust expression in osteoprogenitors, growth plate chondrocytes, and osteoblasts in vivo, which further demonstrates the coexpression of HOXA10 and RUNX2 in osteogenic lineage cells in vivo; (iii) the activation of Runx2 transcription by HOXA10 in mesenchymal cells; (iv) the early recruitment of HOXA10 to target gene chromatin during induction of the osteoblast phenotype, which has consequential effects on acetylation and H3K4 methylation, a signature of active chromatin; and (v) RNAidirected depletion and exogenous expression of HOXA10, which confirm a coordinate change in endogenous expression of Runx2 and osteoblast genes. Further, the demonstration that HOXA10 can directly regulate osteogenic genes in the absence of Runx2 (studies performed with Runx2 Ϫ/Ϫ cells) identifies HOXA10 as a contributor to bone formation independent of Runx2. Together, these results indicate that HOXA10 plays a pivotal role at the onset of osteoblast commitment and may be a significant factor in contributing to osteoblastogenesis by dynamic regulation of osteoblast genes throughout stages of differentiation. Thus, Hoxa10 has a key role in promoting bone tissue formation beyond its requirement for patterning the embryonic skeleton.
Our findings suggest HOXA10 functions in a linear pathway with RUNX2 to promote bone formation as well as independently of RUNX2. Our model ( Fig. 9D ) proposes that HOXA10 functions as an immediate early response gene to the BMP2 signal for the initiation of osteogenic gene regulation and provides an amplification step for RUNX2-induced expression to establish the osteoblast phenotype. As other BMP2-induced transcription factors regulate Runx2 and osteoblastic genes (e.g., homeodomain proteins [MSX2, DLX3, and DLX5], TCF/LEF1, AP-1, OSTERIX, CCAAT/enhancerbinding proteins [encoded by C/EBP], and ATF4) (22, 28, 45, 82, 83, 86) , a compelling question is that of the hierarchy of HOXA10, RUNX2, and these other factors in regulating gene expression for bone formation. Null mouse models have identified OSTERIX function later than RUNX2 (56) . From a developmental perspective, BMP/TGF␤, Wnt, and HOX signaling interactions are documented (5, 62) , and all of these proteins contribute to bone development. From a gene regulation perspective, a hierarchy of transcriptional control can be better deduced by understanding the ordered recruitment of factors to gene promoters and the temporal levels of the regulatory factors during osteoblast differentiation. Abd B class Hoxa10, Msx2, and the distal-less Dlx3 genes are induced within a few hours, while other factors (e.g., Dlx5 and C/EBP␤) are induced later (after 8 h) in the C2C12 model. Recent studies provide evidence from ChIP studies for a homeodomain protein regulatory network for osteoblast commitment and differentiation (35) . Here we show HOXA10 to be associated with bone promoters prior to RUNX2, suggesting that it contributes to the initiation of the osteoblast phenotype. However, increased HOXA10 binding appears to be coordinated with increased recruitment of Runx2, homeodomain proteins, and other factors postproliferatively for accumulation of mRNA, thereby establishing the bone phenotype (35) . The selective temporal binding of HOXA10 to promoters reflects binding and dissociation during differentiation. This is in contrast to the continual increase in RUNX2 binding to promoters, suggesting that HOXA10 has a very dynamic regulatory function for regulating osteogenic gene expression during osteoblast differentiation. We found modifications of histones at the level of chromatin in response to altered HOXA10 expression, indicating a remodeling of the transcriptional machinery that is necessary for in vivo gene regulation. HOXA10 recruitment to bone promoters prior to a significant accumulation of mRNA but after Pol II association emphasizes a functional role for HOXA10 increasing transcription through chromatin remodeling. This is supported by knockdown of HOXA10 reducing histone acetylation and H3K4 methylation, which are associated with active transcription and by HOXA10 and p300/CBP coassociation on the Runx2 and OC promoters (ChIP-reChIP studies). Earlier studies have reported that HOX factors can modify transcriptional activation and repression by interacting with p300/CBP (14, 71) . Our studies have focused on HOXA10 in supporting chromatin remodeling for the activation of osteoblast-related genes, as was shown for p21 (9) . Equally important is the fact that HOXA10 can promote histone deacetylation by recruiting histone deacetylase 2 and SIRT2 histone deacetylases to repress gene transcription (67) . Histone deacetylase-HOXA10 interactions would reverse HAT activity and could be operative in osteoblasts for HOXA10 to mediate either activation or attenuation of gene expression. Such mechanisms are important for HOXA10 suppressor function in undifferentiated myeloid cells and HOXA9 regulation of neovascularization (2, 51, 65, 78) . In addition to coregulatory factors that modify chromatin, the other well-characterized partner proteins for the Abd B HOX proteins, PBX1 and MEIS, both having homeodomain protein modules, form complexes with HOX proteins and also bind to DNA to regulate repressor and enhancer activities of Hox genes. HOXA9, HOXA10, HOXA11, HOXD12, and HOXB13 each have different properties of interaction with these coregulators (52, 61, (72) (73) (74) . For example, high-affinity DNA binding can be achieved when HOXB9 and HOXA10 proteins are dimerized with PBX1. While our forced-expression and siRNA knockdown studies show that HOXA10 has anabolic activity on osteoblast gene expression, how these endogenous partner proteins influence the HOXA10-mediated expression of osteoblast genes is a provocative question. The specificity of HOXA10 for regulating osteoblast differentiation should be considered in relation to Hox nonparalogous and paralogous genes, which are known to overlap in expression in some tissues but can have preferential activities (15, 17, 27) . For example, HOXA10 and HOXD10 regulate the skeleton but may exhibit specific gene regulation properties (36, 49, 79) . Also, HOXA10 and HOX11 homeobox proteins are equivalent for axial but not appendicular skeletal develop- (Table 1) for the indicated gene promoters. The left panel for each gene shows the effect of Hoxa10 siRNA on HOXA10 recruitment in ChIP assay of the indicated promoter. The right panel shows the status of H3K4 methylation or H4 acetylation of the chromatin modification by Hoxa10-specific knockdown. (C) ChIP-reChIP assays were performed to identify the association of coregulatory factors p300 and CBP with HOXA10 on the Runx2 and OC promoters. A HOXA10 ChIP was performed with HOXA10 antibody, and the resulting chromatin immunoprecipitate (second input) was subjected to reChIP with the indicated antibodies (␣) (secondary pull-down). Normal IgG and green fluorescent protein (GFP) antibodies provided controls. The DNA fragments for Runx2 and OC were amplified as described in Materials and Methods. (D) Schematic illustration to show how HOXA10 belongs to an epigenetic coregulatory complex for remodeling chromatin to induce transcription of osteogenic genes. We propose that HOXA10 may be among the earliest factors recruited to bone promoters. HOXA10 recruitment is followed by the coordinated occupancy of other bone-related transcription factors for maximal expression of individual genes during stages of differentiation. HD, homeodomain. (87) . The TTAT regulatory element is recognized by several HOX proteins; however, protein-DNA interactions as well as protein-protein interactions are dependent on the contextual sequence of the core TTAT motif (8, 13, 57) . Our analysis of the functional specificity of the Runx2 Hoxa10 site 1 and no other core motifs in the 0.6-kb Runx2 promoter is consistent with other studies evaluating the specificities of Hoxa10 sites (4, 72, 74) . Although several HOX proteins are likely present in osteoblast nuclear extracts (e.g., HOXA9), our findings revealed a supershifted/block shifted complex by the HOXA10 antibody. However, it is possible that other HOX protein interactions may occur at this and potentially other HOX motifs within the Runx2 gene. Our data do support the concept that the Runx2 site 1 (TTAT) has a high degree of specificity for HOXA10 binding. Interestingly, the OC gene is characterized by a TTAC core motif, implicating this motif in the formation of complexes that support a high degree of OC expression in mature osteoblasts. It is also noteworthy that the flanking nucleotides are distinct among the four target genes studied here (Table 2 ). This finding implies that their sequences may hold information for the dynamic association of HOXA10 with an individual gene throughout differentiation. HOXA10 is expressed in many different tissues in which its functions have been addressed and may be related to its activities in bone tissue. Progesterone and 17␤-estradiol, hormones that regulate turnover of adult bone (53, 63) , increase Hoxa10 expression (16, 48) . HOXA10 regulates hematopoietic differentiation in part via activation of p21 (WAF1/CIP1), the cyclin-dependent kinase inhibitor (9, 25) . In the spinal cord, expression of Hoxa10 is confined to the postmitotic cell population (15) . We find that HOXA10 is expressed in proliferating cells and upregulated in postproliferative mature osteoblasts in vitro. HOXA10 is also a target of induction by vitamin D 3 (66), a hormone that increases the expression of osteoblast-related genes. Thus, HOXA10 appears to have a broad role in gene regulation for contributing to cell differentiation. Our studies have added to the growing recognition that Hox genes have important functions in the adult, including now the skeleton (55) .
In conclusion, our characterization of HOXA10 positive regulation of genes that represent major functional components for bone formation, including those encoding RUNX2 (a bone essential transcription factor), alkaline phosphatase (required for matrix mineralization), bone sialoprotein (an important cell matrix-binding phosphoprotein with hydroxyapatite nucleation capabilities), and OC (the calcium binding bone-specific protein) (47) , solidifies the concept that HOXA10 is an important regulator of gene expression throughout the progression of bone formation. These novel functions for HOXA10 in regulating target genes for osteoblast differentiation and bone formation in the postnatal skeleton have broad implications for HOXA10 functions in normal bone metabolism and bonerelated disorders.
